Latest news for Skylight Health Group (OTC:SLHPF) Stock

Skylight Health Group Inc is a healthcare services and technology company, working to impact patient health outcomes. The company operates a US multi-state health network that comprises physical multi-disciplinary medical clinics providing a range of services from primary care, subspecialty, allied health and diagnostic testing.

SKYLIGHT HLTH GP 9.25 PFD by Skylight Health Group Inc.

Skylight Health Group Inc

News

Rumors

Global

Analyst Ratings

Trading Ideas

Watching Micron Technology; Traders Circulate Analyst Comments Saying "Our Asia Memory Team Is Out Negative On DRAM Pricing Calling For Larger Price Declines In Q4 And Into 1H25; Now See Server DRAM Pricing Up Less Q/Q In Q4 And Down In Q125. See Conventional DRAM Price Declines Peaking In 1H25 And Down, But Less So In 2H25; China's CXMT Remains A Major Risk In 2025 In Terms Of Their Technology And Node Progression And Impact On Broader Industry Supply And Pricing"

The J.M. Smucker Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) shares are trading<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener"> higher on Tuesday.</a>
The company reported second-quarter adjusted earnings per share of $2.76, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42185452/the-j-m-smucker-co-announces-fiscal-2025-second-quarter-results" rel="noreferrer noopener">beating the street view of $2.51.</a>
Quarterly sales of $2.271 billion (+17%) beat the analyst consensus estimate of $2.264 billion.
The increase in comparable net sales reflects a 2 percentage point increase from volume/mix, primarily driven by increases for the&nbsp;Uncrustables,&nbsp;Meow Mix,&nbsp;Café Bustelo, and&nbsp;Jif brands.
U.S. Retail Coffee net sales rose 3% in the quarter under review, U.S. Retail Frozen Handheld and Spreads increased 5%, and U.S. Retail Pet Foods decreased&nbsp;4%.
Gross profit increased 22%, reflecting a favorable impact from the acquisition of Hostess Brands, favorable volume/mix, higher net price realization, and lower costs.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42185644/us-stocks-may-have-a-slow-start-as-trumps-tariff-threat-begins-to-thwart-relief-rally-analysts-remain-positive-on-market-breadth-ai-linked-sectors-and-stocks" rel="noreferrer noopener">US Stocks May Have A Slow Start As Trump&#8217;s Tariff Threat Begins To Thwart Relief Rally: Analysts Remain Optimistic About AI-Linked Sectors Stocks</a>
Operating cash flow was&nbsp;$404.2 million, compared to&nbsp;$176.9 million&nbsp;in the prior year. Free cash flow was&nbsp;$317.2 million, compared to&nbsp;$28.2 million&nbsp;in the prior year.
&#8220;Looking ahead, we are focused on delivering our strategic priorities, including the integration of Hostess Brands, and are taking decisive actions to grow the&nbsp;Hostess&nbsp;brand,&#8221; said&nbsp;Mark Smucker, Chair of the Board, President and Chief Executive Officer.
Outlook: The J.M. Smucker Company has revised its fiscal year 2025 adjusted earnings per share (EPS) forecast to a range of $9.70 to $10.10 versus $9.78 estimate, slightly above the previous forecast of $9.60 to $10.00 and <a href="https://www.benzinga.com/calendars/guidance">continues to anticipate net sales growth of 8.5% to 9.5%.</a>
Price Action: SJM shares are trading higher by 5.37% to $119.72 premarket at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42180029/ark-invest-shakes-up-portfolio-with-big-tesla-and-amazon-trades" target="_blank" rel="noreferrer noopener">Cathie Wood-Led Ark Invest's Latest Portfolio Maneuver: Dumps Tesla And Palantir Shares, Buys Amazon And AMD Stock</a></li>
</ul>
Photo by Willis Lam <a href="https://www.flickr.com/photos/85567416@N03/15820668979" target="_blank" rel="noreferrer noopener">via Flickr</a>.

Earnings

Equities

Guidance

Markets

Movers

General

J.M. Smucker Q2: Earnings Beat, 17% Sales Surge, FY25 EPS Outlook Boost & More

Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) will release earnings results for the third quarter, after the <a href="https://www.benzinga.com/quote/dell/earnings">closing bell, on Tuesday.</a>
Analysts expect the Round Rock, Texas-based company to report quarterly earnings at $2.06 per share, up from $1.88 per share in the year-ago period. Dell is expected to report quarterly revenue of $24.72 billion, compared to $22.25 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Last week, Dell announced an expansion of its Dell Integrated Rack Scalable Systems (IRSS) program to include the Dell PowerEdge XE9685L and Dell PowerEdge XE7740 servers in the standard 19-inch Dell Integrated Rack 5000. The new liquid and air-cooled Dell PowerEdge XE servers deliver advanced compute at scale and simplify data access for AI.
With the recent buzz around Dell ahead of quarterly earnings, some investors may be eyeing potential gains from the company's dividends too. As of now, Dell offers an annual dividend yield of 1.23%, which is a quarterly dividend amount of 44.5 cents per share ($1.78 a year).
To figure out how to earn $500 monthly from Dell, we start with a yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Dell's $1.78 dividend: $6,000 / $1.78 = 3,371 shares.
So, an investor would need to own approximately $485,963 worth of Dell, or 3,371 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $1.78 = 674 shares, or $97,164 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
DELL Price Action: Shares of Dell slipped by 0.03% to close at $144.16 on Monday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42174548/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Tech

DELL

How To Earn $500 A Month From Dell Stock Ahead Of Q3 Earnings

Canaccord Genuity analyst Austin Moeller maintains Vertical Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) with a Buy and raises the price target from $15 to $16.

Price Target

EVTL

Canaccord Genuity Maintains Buy on Vertical Aerospace, Raises Price Target to $16

Biotech

LTRN

Lantern Pharma & Starlight Therapeutics Announce Presentation Of LP-184  Phase 1b Trial Design And Preclinical Data In Glioblastoma At Society for Neuro-Oncology 2024

Canaccord Genuity analyst Brian McNamara maintains Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) with a Buy and lowers the price target from $48 to $45.

CENT

Canaccord Genuity Maintains Buy on Central Garden & Pet, Lowers Price Target to $45

Canaccord Genuity analyst Kingsley Crane maintains Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) with a Buy and lowers the price target from $28 to $25.

ALAR

Canaccord Genuity Maintains Buy on Alarum Technologies, Lowers Price Target to $25

Barclays analyst Nicholas Campanella maintains Xcel Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>) with a Overweight and raises the price target from $67 to $71.

Barclays Maintains Overweight on Xcel Energy, Raises Price Target to $71

Critical Metals Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRML#NASDAQ">CRML</a>) ("Critical Metals Corp" or "the Company"), a leading mining development company focused on critical metals and minerals and producing strategic products essential to electrification and next generation technologies for Europe and its western world partners, today provided a project update for the Tanbreez Greenland Rare Earth Mine (the "Tanbreez Project"), one of the world's largest rare earth assets located in Southern Greenland. In connection to the drilling, the Company has discovered one of the world's highest concentrations of Gallium, an essential rare earth element for the production of computer chips and defense applications.
Based on initial results obtained from Critical Metals Corp's recent drilling program, four high-grade zones have now been identified on the site. These zones are expected to play a significant role in the Company's strategy for optimizing its mining operations and increasing throughput (the Tanbreez Project is currently licensed for 500,000 metric tons per year). The identification of these zones is a key milestone in the ongoing development of the project.

CRML

Critical Metals Corp Discovers 147 PPM Of Gallium At Its Tanbreez Project; Says "4 High-Grade Zones Have Now Been Identified On The Site, Zones Are Expected To Play A Significant Role In The Co's Strategy For Optimizing Its Mining Operations And Increasing Throughput"

Barclays analyst Jared Shaw maintains Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) with a Overweight and raises the price target from $24 to $26.

Barclays Maintains Overweight on Old National, Raises Price Target to $26

The Q3 earnings report for Icecure Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) was released on Tuesday, November 26, 2024 at 08:30 AM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Icecure Medical missed estimated earnings by 0.0%, reporting an EPS of $-0.08 versus an estimate of $-0.08.
Revenue was up $335 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
The company beat on EPS by $0.01 in the previous quarter, leading to a 1.0% drop share price change the next day.
Here's a look at Icecure Medical's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.07</td>
<td>-0.08</td>
<td>-0.07</td>
<td>-0.07</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.06</td>
<td>-0.08</td>
<td>-0.07</td>
<td>-0.09</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>930K</td>
<td>880K</td>
<td>1.17M</td>
<td>1.17M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.01M</td>
<td>743K</td>
<td>1.25M</td>
<td>327K</td>
</tr>
</tbody>
</table>

To track all earnings releases for Icecure Medical <a href="https://www.benzinga.com/quote/ICCM/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ICCM

Icecure Medical Earnings Review: Q3 Summary

<a href="https://www.globenewswire.com/Tracker?data=SRbbH_fWlobCg0PXl43R4xu6d8j-iiHze5ibnZvXOE-EUFeq0DTq1-ZiYMfddeEknmQ9vK-IILuugPVrukJjUQ==">Gelteq Limited</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) ("Gelteq" or the "Company"), a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, announces today that in November, 400,000 units of its gel solution are entering into production. These units will fulfill orders made for clients in the U.S and Australia. Delivery is expected in January 2025 for sales across the two countries as well as in the UAE and in Asia. The production run includes Gelteq nutraceutical products in the areas of sports, anti-aging, and weight loss.
Gelteq Co-Founder and CEO Nathan Givoni stated, "Our recent IPO was undertaken to provide the necessary capital and awareness of our technology to commence larger scale sales, whilst balancing our research and development activities. To see such volumes entering production so soon after the IPO is a testament to our team executing our plans, together with market validation on our gel-based technology. This production run demonstrates our ability to sell our products to end-users across the world and our ability to begin deriving revenues in the near term."
Gelteq Co-Founder and Executive Chairman Simon Szewach stated, "Earlier this year, we strengthened our partnership with Monash Innovation Labs, which allows us to effectively scale and meet our client needs, while ensuring the quality of products. The orders connected to this production run are substantial and we believe that they represent the start of even larger volume orders to come."

GELS

Gelteq Announces That In November, 400,000 Units Of Its Gel Solution Are Entering Into Production; Units Will Fulfill Orders Made For Clients In The U.S And Australia; Delivery Is Expected In January 2025 For Sales Across The Two Countries As Well As In The UAE And In Asia

TPET

Trio Petroleum Secures Option Extension To Acquire Remaining 17.75% Working Interest Of Asphalt Ridge To Feb. 10, 2025

Betting activity on Polymarket suggests significant skepticism about President-elect Donald Trump's promise to impose a <a href="https://www.benzinga.com/24/11/42178994/trump-says-he-will-impose-25-tariffs-on-canada-mexico-on-first-day-of-office-and-extra-tariffs-on-china-until-they-pay-attention">25% tariff on goods</a> from Mexico and Canada.
What Happened: As of now, market <a href="https://polymarket.com/event/will-trump-impose-25-tariff-on-mexicocanada?tid=1732619786757">odds</a> give the tariff's implementation only a 30% chance by the proposed Jan. 31, 2025 deadline, despite Trump's strong rhetoric on the issue.
Trump on Monday announced his intention to implement the tariff as part of his first executive orders after taking office. 
In a <a href="https://truthsocial.com/@realDonaldTrump/posts/113546215051155542">statement</a> on Truth Social, Trump said, "On January 20th, I will sign all necessary documents to charge Mexico and Canada a 25% Tariff on ALL products coming into the United States." He justified the measure as a response to the &#8220;invasion&#8221; of illegal immigrants and drugs, including fentanyl, coming across the U.S. borders with Mexico and Canada.
He added, "This tariff will remain in effect until such time as Drugs, in particular Fentanyl, and all Illegal Aliens stop this Invasion of our Country!"
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42172993/bitcoin-slides-below-95000-analyst-predicts-potential-correction-to-85000">Bitcoin Slides Below $95,000 — Analyst Predicts Potential Correction To $85,000</a>
Why It Matters: Polymarket bettors remain skeptical about the feasibility of Trump's tariff plan.
While the statement has stirred political and economic debate, only 30% of bettors currently believe that the tariff will be implemented by the specified date. 
The remaining 70% seem to view the promise as unlikely to materialize within the stated timeframe, citing potential political hurdles, economic implications and international pushback.
If enacted, the tariff could significantly impact trade relations between the United States and its neighboring countries. Canada and Mexico are two of the U.S.'s largest trading partners, with billions of dollars in goods crossing the borders daily. 
<a href="https://www.benzinga.com/24/11/42178994/trump-says-he-will-impose-25-tariffs-on-canada-mexico-on-first-day-of-office-and-extra-tariffs-on-china-until-they-pay-attention">Economists have warned</a> that such tariffs could disrupt supply chains and increase costs for American consumers.
Inflation may bump permanently back over 3% if a universal tariff is enacted, <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42042411/inflation-could-surge-to-3-if-trump-applies-universal-tariffs-goldman-sachs">according to Goldman Sachs</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42171439/solana-meme-coin-platform-pump-fun-faces-backlash-over-scandalous-livestreams-but-polymarket-traders-arent-convinced-theyll-go-dark">Solana Meme Coin Platform Pump.Fun Faces Backlash Over Scandalous Livestreams, But Polymarket Traders Aren&#8217;t Convinced It&#8217;ll Go Dark</a></li>
</ul>
Image: Wikimedia

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Trump Threatens 25% Tariffs On Canada, Mexico Until 'Invasion' Is Stopped, But Polymarket Traders Aren't Convinced

Truist Securities analyst Michael Ciarmoli reiterates Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) with a Buy and raises the price target from $187 to $226.

Reiteration

Truist Securities Reiterates Buy on Woodward, Raises Price Target to $226

Barclays analyst Matt Miksic maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Overweight and raises the price target from $105 to $109.

Barclays Maintains Overweight on Medtronic, Raises Price Target to $109

FEMY

Femasys Announces Peer-Reviewed Publication Of FemaSeed Data In The Journal of Gynecology & Reproductive Medicine

Tsakos Energy Navigation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) reported quarterly earnings of $0.67 per share which beat the analyst consensus estimate of $0.66 by 1.52 percent. This is a 19.28 percent decrease over earnings of $0.83 per share from the same period last year. The company reported quarterly sales of $200.16 million which beat the analyst consensus estimate of $164.00 million by 22.05 percent. This is a 7.23 percent increase over sales of $186.66 million the same period last year.

Tsakos Energy Navigation Q3 EPS $0.67 Beats $0.66 Estimate, Sales $200.16M Beat $164.00M Estimate

Barclays analyst Adrienne Yih maintains Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) with a Underweight and raises the price target from $28 to $34.

BBWI

Barclays Maintains Underweight on Bath & Body Works, Raises Price Target to $34

Truist Securities analyst Patrick Scholes maintains Travel+Leisure (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNL#NYSE">TNL</a>) with a Buy and raises the price target from $60 to $61.

Comments

Skylight Health Group

News

Latest news for Skylight Health Group (OTC:SLHPF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga